Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.

Migang Kim Chi-Son Chang Min Chul Choi Jeong-Won Lee Hyun Park Won Duk Joo

Published in: Yonsei medical journal (2023)

These results suggest that responses to ICI rechallenge are not as intolerable as responses to previous ICI. Clinicians should carefully consider rechallenge with PD-1 inhibitors outside of clinical trials until there are sufficient data to routinely support this practice.

Keyphrases

clinical trial
healthcare
primary care
palliative care
electronic health record
big data
quality improvement
endometrial cancer
machine learning
deep learning
phase iii
open label
placebo controlled